Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Articles

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their pharmacies through network exclusions and targeted marketing. 

Insurer-PBM Firms Dominate Medicare Part D Market, Steering Patients to Their Pharmacies

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.


Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

Mutations in one of the first human-isolated strains of H5N1 bird flu in the US were identified by the Texas Biomedical Research Institute.

New Insights Into H5N1 Variability in Human Mutations

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial. 

FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Biosimilars Unveiled: Current Trends, Challenges, and Future Opportunities in the US Marketplace

Video Series

Out of Pocket Costs Associated with Biosimilar Use 

Videos

Biosimilar utilization considerations in the current health care landscape are explored by an esteemed panel of medical professionals.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.

Biologics Utilization Impacting US Health Care Spending 

Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.

Current Landscape of Biosimilar Use in US Healthcare Space

The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.

Interchangeability Impacting Biosimilar Uptake

Dr. Cannon leads a conversation navigating the impact of payer coverage on the uptake of biosimilars.

The Impact of Payer Coverage and Reimbursement on Biosimilars

The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.

Navigating Biosimilar Uptake in New Patients

The panel discusses the economic impact biosimilars have across different patient types.

Economic Impacts and Pricing Strategies Surrounding Biosimilars

The expert panel discusses the greater potential for private label biosimilars.

Private Label Biosimilars

Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.

Biosimilars in the Commercial Sector

The panel discusses how employer preferences influence the strategies and decisions of payers/PBMs.

The Influence of Employer Preferences And Adoption of Biosimilars

The panel discusses out of pocket costs and the impact of the 340b program for various patient types. 

Dr. Tichy discusses unmet needs he deems crucial for the continued uptake of biosimilars. 

Unmet Needs and Future Initiatives

The panel discusses ideal goals for biosimilar utilization.

Ideal Goals for Biosimilar Utilization

The expert panel discuss future trends in the biosimilar space.

Foreseeable Biosimilar Trends

The expert panel discuss the importance of legislative support to continue innovations in the biosimilar space. 

Legislative Support for Biosimilars

The panelists provide their closing thoughts, highlighting key considerations around biosimilar.

Key Takeaways for Biosimilar Utilization

Out of Pocket Costs Associated with Biosimilar Use

EP: 1.Biologics Utilization Impacting US Health Care Spending

EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space

EP: 3.Interchangeability Impacting Biosimilar Uptake

EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars

EP: 5.Navigating Biosimilar Uptake in New Patients

EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 7.Private Label Biosimilars

EP: 8.Biosimilars in the Commercial Sector

EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars

EP: 10.Out of Pocket Costs Associated with Biosimilar Use

EP: 11.Unmet Needs and Future Initiatives

EP: 12.Ideal Goals for Biosimilar Utilization

EP: 13.Foreseeable Biosimilar Trends

EP: 14.Legislative Support for Biosimilars

EP: 15.Key Takeaways for Biosimilar Utilization